Zomedica Corp. ZOMDF

Zomedica announced a strategic partnership with Veterinary Management Groups (VMG) to provide its diagnostic and therapeutic technologies to VMG’s member network, spanning over 2,000 U.S. practices, from September 1, 2026 to August 31, 2028. VMG members will receive preferred access to PulseVet shock wave therapy, Assisi tPEMF devices, VETIGEL hemostatic gel, the TRUFORMA point-of-care diagnostic platform (including ACTH, cortisol, and progesterone testing), and the VETGuardian PLUS remote monitoring system. The deal aims to expand adoption across independent practices, enhancing clinical outcomes, operational efficiency, and revenue opportunities for Zomedica. Quotes from Zomedica CEO Larry Heaton and VMG President Matt Salois emphasize empowering independent clinics and elevating care. Zomedica’s TAM exceeds $2B; 2025 revenue was $32M with about $44M in liquidity as of June 30, 2026. Forward-looking statements and risk disclosures apply. Expands distribution to ~2,000 independent clinics, potentially accelerating revenue growth and market share.

Zomedica Corp. announces strategic collaboration with Boehringer Ingelheim Animal Health Canada Inc. to expand equine endocrine diagnostic testing using TRUFORMA platform. Partnership expands TRUFORMA platform reach in equine diagnostics, likely driving revenue growth and stronger market positioning.

Zomedica Corp. reported record Q2 revenue of $9.5 million, up 37% year-over-year, with net loss reduced 49% and $44.1 million in liquidity. Record revenue growth combined with sharply lower net loss signals stronger financial results likely to lift stock performance and investor outlook.

Zomedica Corp. (ZOMDF) announces 'Fifth Friday at Four' webinar on May 29th to present First Quarter 2026 financial results and conduct a deep dive into the Companion Animal VetTech Market. Webinar on upcoming Q1 2026 financials and VetTech market analysis will likely influence investor sentiment and highlight operational insights without transformative changes.

Zomedica Corp. (ZOMDF) reports record first-quarter revenue of $8.8 million, up 35% year-over-year, with $47.5 million in liquidity. Record revenue growth of 35% and substantial liquidity enhance financial stability and investor confidence in Zomedica's growth trajectory.

Zomedica announces strategic collaboration with Boehringer Ingelheim to expand equine endocrine diagnostic testing using the TRUFORMA platform. Strategic partnership with major animal health player Boehringer Ingelheim boosts Zomedica's equine diagnostics expansion and competitive positioning.

Zomedica Corp. announces record fourth quarter revenue of $10.5 million and full year revenue of $32.0 million for 2025, reflecting 17% annual growth, 68% gross margin, and $53.3 million in liquidity. Record revenues with 17% growth, 68% gross margins, and strong liquidity position significantly enhance financial performance and investor sentiment.

Zomedica Corp. expands distribution of its TRUVIEW Digital Microscopy Platform through a national agreement with Moichor, a leader in veterinary pathology. National agreement with a veterinary pathology leader significantly broadens TRUVIEW platform distribution and supports revenue growth.

Zomedica Corp. announced its upcoming 'Fourth Friday at Four' webinar scheduled for February 27th, which will focus on the company's research and development efforts as well as its innovation pipeline. This event aims to provide insights into Zomedica's strategic initiatives and future product offerings. The webinar may provide valuable insights into Zomedica's innovation pipeline, potentially influencing investor sentiment and market performance.

Zomedica Corp. has expanded its TRUVIEW(R) microscopy platform by integrating AI diagnostic interpretation, which is expected to enhance its capabilities in veterinary diagnostics. This advancement aims to improve the accuracy and efficiency of diagnostic processes, potentially increasing the company's market opportunity in the veterinary sector. The integration of AI into the TRUVIEW(R) platform represents a significant strategic move that could enhance product offerings and market positioning.

Zomedica Corp. has entered into a contract manufacturing and services agreement with Rahm Sensor Development, aiming to diversify its revenue streams beyond the animal health sector. This partnership is expected to leverage Rahm's expertise in sensor technology, potentially enhancing Zomedica's product offerings and market reach. The agreement represents a significant strategic move that could expand Zomedica's market presence and revenue sources.

Zomedica Corp. announced its upcoming 'Fourth Friday at Four' webinar scheduled for January 23rd, focusing on digital innovation and technology-driven growth. The event aims to highlight the company's advancements in veterinary diagnostics and its commitment to leveraging technology for enhanced product offerings. The webinar may influence investor sentiment and showcase potential innovations, but its immediate impact on financial performance is expected to be limited.

Zomedica Corp. has launched the next-generation VETGuardian PLUS(TM) Monitor, enhancing its core monitoring platform aimed at the growing veterinary market. This new device is designed to provide advanced monitoring capabilities for veterinary professionals, reflecting Zomedica's commitment to innovation in animal health technology. The launch of a next-generation monitoring device is a significant strategic move that could enhance Zomedica's competitive position in the veterinary market.

Zomedica Corp. has announced a collaboration with Prime Video, featuring its Assisi Loop® products in the new holiday film 'Merv.' This partnership aims to enhance brand visibility and promote the company's innovative veterinary products through a popular entertainment platform. The collaboration with Prime Video may enhance brand awareness and market sentiment, but its overall impact on financial performance is expected to be limited.

Zomedica Corp. has expanded its TRUFORMA(R) diagnostic menu with the launch of a new Equine Progesterone Assay. This addition aims to enhance the company's offerings in veterinary diagnostics, particularly for equine health management. The assay is designed to provide accurate and timely results, supporting veterinarians in making informed decisions regarding equine reproductive health. The launch of the Equine Progesterone Assay is expected to moderately influence Zomedica's product innovation and market positioning in the veterinary diagnostics sector.

Zomedica Corp. announced a webinar titled 'Friday at Four' scheduled for November 21st, which will provide a strategic overview and a review of its business performance for the third quarter of 2025. The event aims to inform stakeholders about the company's developments and future direction. The webinar may influence investor sentiment and provide insights into the company's performance, but its overall effect is expected to be limited.

Zomedica Corp. has achieved ISO 13485 certification, which highlights its commitment to quality management systems in the design and manufacturing of medical devices. This certification is expected to enhance the company's operational capabilities and commercial potential, positioning it favorably in the veterinary diagnostics market. The achievement reflects Zomedica's focus on quality infrastructure as it prepares for future product launches and market expansion. ISO 13485 certification significantly enhances Zomedica's credibility and operational readiness, likely impacting its market positioning and investor sentiment.

Zomedica Corp. reported its third quarter 2025 financial results, showing a 16% increase in revenue to $8.1 million and achieving gross margins of 67%. The company also highlighted its strong liquidity position with $54 million available to support future growth initiatives. The significant revenue growth and strong liquidity position indicate a positive trajectory for Zomedica's future performance and market sentiment.

Zomedica Corp. has launched the Assisi Loop Lounge, a new therapy product utilizing scientifically backed tPEMF technology for pets. This innovative product aims to enhance the healing process for animals by providing targeted pulsed electromagnetic field therapy, which is designed to alleviate pain and promote recovery. The launch reflects Zomedica's commitment to advancing veterinary care and expanding its product offerings in the pet health market. The introduction of a new therapeutic product could significantly enhance Zomedica's market position and revenue potential in the veterinary sector.

Zomedica Corp. has expanded its distribution agreement with Grovet to include its diagnostic and therapeutic device products throughout the European Union. This move aims to enhance Zomedica's market presence and accessibility of its veterinary products in the region, potentially increasing sales and brand recognition. Expanding distribution agreements in the EU is a significant strategic move that could enhance market reach and revenue potential.

Zomedica Corp. will feature its VETGuardian(R) Zero Touch(TM) Monitor in an upcoming webinar titled 'Fourth Friday at Four' scheduled for October. This event aims to showcase the innovative veterinary monitoring technology designed to enhance pet healthcare. The webinar could moderately influence market sentiment and product awareness, impacting Zomedica's competitive positioning.

Zomedica Corp. has expanded its TRUFORMA(R) diagnostic platform to include feline applications for its Cobalamin and Folate assay. This addition aims to enhance diagnostic capabilities for veterinarians treating cats, addressing a significant need in feline healthcare. The company continues to focus on developing innovative solutions for animal health, positioning itself to better serve the veterinary market. The expansion of the TRUFORMA platform to include feline use is expected to moderately influence Zomedica's market position and product offerings.

Zomedica Corp. has expanded its intellectual property portfolio with the issuance of four new U.S. patents related to its TRUVIEW(R) and TRUFORMA(R) products. These patents enhance the company's position in the veterinary diagnostics market, supporting its ongoing innovation and product development efforts. The new intellectual property is expected to strengthen Zomedica's competitive edge and potentially drive future growth. The issuance of new patents is a significant strategic move that can enhance Zomedica's competitive position and market potential.

Zomedica Corp. is hosting its fourth 'Friday at Four' webinar, focusing on the TRUVIEW(R) Digital Cytology Microscope, which aims to enhance veterinary imaging. The event will showcase the microscope's capabilities and its potential impact on veterinary diagnostics, emphasizing Zomedica's commitment to innovation in the veterinary field. The introduction of the TRUVIEW(R) Digital Cytology Microscope represents a significant advancement in veterinary imaging that could enhance Zomedica's market position and investor sentiment.

Zomedica Corp. has expanded its distribution agreement with UXR in Canada, enhancing the availability of its veterinary diagnostic products. This agreement aims to improve market access and support Zomedica's growth strategy in the Canadian veterinary sector. The collaboration is expected to strengthen Zomedica's presence and drive sales in the region. The expanded distribution agreement is likely to moderately influence Zomedica's market presence and sales performance in Canada.

Zomedica Corp. has entered into a strategic distribution agreement to enhance its presence in the UK market, focusing on its innovative veterinary product portfolio. This partnership aims to capitalize on the growing demand for veterinary solutions, positioning Zomedica for increased market penetration and revenue growth in the region. The strategic distribution agreement is expected to significantly enhance Zomedica's market position and revenue potential in the UK.

Zomedica Corp. has entered into a strategic partnership with VerticalVet to enhance the delivery of advanced veterinary technologies to independent veterinary practices. This collaboration aims to provide innovative solutions that improve operational efficiency and patient care within these practices, ultimately benefiting both veterinarians and pet owners. The partnership is expected to significantly enhance Zomedica's market position and product offerings in the veterinary sector.

Zomedica Corp. announces the return of its Fourth Friday at Four Webinar, focusing on the VETIGEL(R) hemostatic product, which aims to enhance rapid bleeding control in veterinary medicine. The webinar will provide insights into the product's development and its potential impact on veterinary practices. The spotlight on VETIGEL(R) indicates a significant strategic focus that could enhance Zomedica's competitive positioning in the veterinary market.

Zomedica Corp. reported its second quarter 2025 financial results, showing a 14% increase in revenue to $7 million and achieving gross margins of 67%. The company also highlighted its strong liquidity position with $59 million available to support future growth initiatives. The significant revenue growth and strong liquidity position indicate a positive trajectory for the company's future performance.

Zomedica Corp. will host its Fourth Friday at Four webinar on July 25, 2025, focusing on the Assisi line of targeted Pulsed Electromagnetic Field (tPEMF) therapy devices for pets. The session will cover the science behind tPEMF therapy, success stories, and integration into veterinary care, featuring an interactive Q&A. Zomedica aims to highlight the benefits of drug-free healing solutions for animals, showcasing their commitment to innovation in veterinary care. The webinar emphasizes significant advancements in veterinary technology that could enhance Zomedica's market position and investor sentiment.